Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.
By CNBC ยท CNBC
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.